Chemiluminescence Analyzer (CLA) Market Size, Share, Growth, and Industry Analysis, By Type (Benchtop, Floor-Standing), By Application (Hospitals and Diagnostic Centers, Research Laboratories, Pharma and Biotech Companies, Academic Research Centers), Regional Insights and Forecast From 2025 To 2033

• 

  Request a Free sample to learn more about this report

CHEMILUMINESCENCE ANALYZER (CLA) MARKET OVERVIEW

The global chemiluminescence analyzer (cla) market, valued at USD 16.51 billion in 2024, is projected to grow steadily to USD 17.81 billion in 2025 and reach USD 32.68 billion by 2033, maintaining a CAGR of 7.9% from 2025 to 2033.

A chemiluminescence analyzer (CLA) is a scientific instrument used for the quantitative measurement of chemiluminescent reactions. Chemiluminescence refers to the emission of light that occurs when a chemical reaction produces an excited state species that subsequently emits photons as it returns to its ground state. CLAs are designed to detect and measure this light emission, allowing for the analysis of various chemical and biological samples.

CLA instruments are commonly used in analytical chemistry, biochemistry, environmental monitoring, and clinical diagnostics. They are particularly useful for the detection and quantification of substances that produce chemiluminescent reactions, such as certain enzymes, reactive oxygen species, and specific analytes in biological and environmental samples.

CHEMILUMINESCENCE ANALYZER (CLA) MARKET KEY FINDING

• Market Size and Growth: Global chemiluminescence analyzer (cla) market, valued at USD 16.51 billion in 2024, is projected to grow steadily to USD 17.81 billion in 2025 and reach USD 32.68 billion by 2033, maintaining a CAGR of 7.9% from 2025 to 2033.

• Key Market Driver: In 2022, an estimated 20 million new cancer cases worldwide underscored rising demand for high-sensitivity immunoassay testing.

• Major Market Restraint: Only 39% of surveyed countries included basic immunoassay analyzer services in their universal health coverage packages in 2024, limiting market accessibility.

• Emerging Trends: The consumables segment accounted for 66.45% of the chemiluminescence immunoassay market share in 2023, reflecting growing emphasis on reagent-based business models.

• Regional Leadership: North America led global CLIA analyzer adoption in 2023, holding a 40.7% market share in immunoassay analyzers.

• Competitive Landscape: According to Kalorama Information, Roche, Abbott, Siemens Healthineers, Beckman Coulter and Alere together capture over 40 % of the global immunoassay analyzer market.

• Market Segmentation: By throughput, high-throughput CLIA analyzers dominated in 2022, serving large-volume clinical labs and representing the fastest-growing device category.

• Recent Development: In January 2025, Roche launched its cobas® e 801 analytical unit, capable of up to 300 immunochemistry tests per hour with 48 onboard reagent positions.

COVID-19 IMPACT

Pandemic Hampered the Demand for Market

The COVID-19 pandemic has had a significant impact on various industries, including the healthcare and medical devices sectors. The Chemiluminescence Analyzer (CLA) market, which includes instruments used for diagnostic testing, has also been affected by the pandemic. The pandemic caused disruptions in global supply chains, affecting the production and distribution of CLA instruments. Lockdown measures, restrictions on international trade, and transportation disruptions led to delays in the delivery of raw materials, components, and finished products. This resulted in manufacturing slowdowns and supply shortages, impacting the availability of CLA instruments in the market. Many hospitals and healthcare facilities had to postpone or cancel elective procedures during the peak of the pandemic. This reduction in non-essential medical services led to decreased demand for CLA instruments, as these instruments are commonly used for various diagnostic tests and monitoring of diseases other than COVID-19. The decline in elective procedures negatively impacted the overall market demand for CLA instruments.

LATEST TRENDS

Increasing Demand in Pharmaceutical Industries to Fuel Market Growth

Chemiluminescence Analyzer (CLA) are extensively used in drug discovery, clinical diagnostics, and life science research. The growing focus on drug development, biomarker identification, and genomics has increased the demand for CLA systems. The market has seen technological advancements, leading to improved sensitivity, multiplexing capabilities, and automation. These developments have enhanced the accuracy and efficiency of CLA systems, making them more attractive to end-users. CLAs are employed in environmental monitoring to detect and quantify pollutants, contaminants, and toxins. The increasing awareness of environmental issues and the need for monitoring water quality, air pollution, and soil contamination have contributed to the market growth. CLAs have found significant utility in clinical laboratories for diagnosing diseases, monitoring therapeutic drug levels, and detecting biomarkers. The rising prevalence of chronic diseases, such as cancer and infectious diseases, has driven the adoption of CLA systems in clinical settings.

• According to the CDC’s NHANES Laboratory Procedure Manual, the immunoassay module (e801) of the Roche/Hitachi Cobas 8000 series can perform up to 300 chemiluminescence immunoassay tests per hour, reflecting the industry shift toward ultra–high‐throughput platforms in clinical laboratories.

• As reported in WHO’s Prequalification Technical Specifications, 49 in vitro diagnostic manufacturers were pursuing WHO prequalification for third‐generation immunoassays (including chemiluminescent methods) as of 2019, underscoring growing R&D investment in CLI technology.

Request a Free sample to learn more about this report

CHEMILUMINESCENCE ANALYZER (CLA) MARKET SEGMENTATION

By Type

According to type, the market can be segmented into Benchtop, Floor-Standing.

By Application

Based on application, the market can be divided into Hospitals and Diagnostic Centers, Research Laboratories, Pharma and Biotech Companies, Academic Research Centers.

DRIVING FACTORS

Increasing Demand for Clinical Diagnostics to Stimulate Market Growth

Chemiluminescence Analyzer (CLA) are widely used in clinical diagnostics to detect and quantify various analytes, including hormones, proteins, antibodies, and infectious agents. With the growing prevalence of chronic diseases, such as cancer, cardiovascular diseases, and infectious diseases, there is a rising demand for accurate and sensitive diagnostic tools, which is driving the adoption of CLA . Technological advancements in chemiluminescence analyzers have led to improved performance, increased sensitivity, and enhanced automation capabilities. These advancements have made the analyzers more efficient, reliable, and user-friendly, thereby driving their adoption across various applications.

Growing Development of Multiplexing Capabilities to Boost Market Growth

 The development of multiplexing capabilities in chemiluminescence analyzers has further expanded their utility, allowing simultaneous detection of multiple analytes in a single sample. Early detection and diagnosis of diseases play a crucial role in effective treatment and patient outcomes. CLA offers high sensitivity and accuracy, enabling the detection of low levels of analytes in clinical samples. As a result, there is a growing awareness among healthcare professionals and patients about the benefits of early disease detection, driving chemiluminescence analyzer (CLA) market growth.

• Data from five U.S. laboratories showed that 140,176 serum specimens were processed using reverse‐sequence syphilis screening with chemiluminescence immunoassays, of which 56.7 percent required reflex nontreponemal testing—highlighting rising demand for accurate, high‐sensitivity analyzers in public health settings.

• The FDA 510(k) Premarket Notification Database lists 7 paramagnetic‐particle chemiluminescence immunoassay assays cleared for clinical use in the first five months of 2024, demonstrating strong regulatory support that is accelerating assay availability.

RESTRAINING FACTORS

High Initial Investments to Restrict Market Growth

Chemiluminescence Analyzer (CLA) are complex and sophisticated instruments that require significant investment in terms of research and development, manufacturing, and quality control. The high initial investment required to develop and produce these analyzers can be a restraint for smaller companies or organizations with limited financial resources.

• In the CDC‐reported syphilis screening study, between 12.2 percent and 60.0 percent of EIA/CIA reactive specimens were later found to be false positives, underscoring ongoing concerns about specificity in certain clinical applications.

• WHO prequalification guidelines stipulate that chemiluminescent assay reagents require cold‐chain storage (2–8 °C) with on‐board stability of only 4 weeks after opening, creating logistical challenges for 68 member states lacking reliable refrigerated transport infrastructure.

• Request a Free sample to learn more about this report

•  

CHEMILUMINESCENCE ANALYZER (CLA) MARKET REGIONAL INSIGHTS

Advanced Health Infrastructure in North America region to Drive Market Expansion

North America region holds the leading position in chemiluminescence analyzer (CLA) market share. The region has a well-developed healthcare infrastructure, a strong emphasis on research and development, and a high demand for advanced diagnostic technologies. Major pharmaceutical and biotechnology companies, as well as academic and research institutions, drive the demand for CLA systems in North America.

KEY INDUSTRY PLAYERS

Adoption Innovative Strategies by Key Players Influencing Market Growth

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio.

The top key players in the market are Abbott Laboratories, Beckman Coulter, bioMérieux SA, F. Hoffmann-La Roche, Siemens Healthineers, Biokit, DiaSorin, Ortho Clinical Diagnostics. The strategies to develop new technologies, capital investment in R&D, improve product quality, acquisitions, mergers, and compete for the market competition help them to perpetuate their position and value in the market. Besides, collaboration with other companies & extensive possession over market shares by the key players stimulates market demand.

• Abbott Laboratories: According to FDA 510(k) K233932, Abbott’s Alinity i Toxo IgM chemiluminescent microparticle immunoassay was cleared in mid-2024 for qualitative detection of Toxoplasma gondii antibodies—its third CLIA-based assay launch within twelve months.

• Beckman Coulter: As per FDA 510(k) K232904, Beckman Coulter’s Access Ostase bone alkaline phosphatase assay received clearance in April 2024, capable of performing up to 30 tests per hour on the DxI 9000 system, thereby expanding the company’s CLI analyzer offerings.

List of Top Chemiluminescence Analyzer (Cla) Companies

• Abbott Laboratories
• Beckman Coulter
• bioMérieux SA
• F. Hoffmann-La Roche
• Siemens Healthineers
• Biokit
• DiaSorin
• Ortho Clinical Diagnostics

REPORT COVERAGE

This report examines an understanding of the Chemiluminescence analyzer (CLA) market’s size, share, and growth rate, segmentation by type, application, key players, and previous and current market scenarios. The report also collects the market’s precise data and forecasts by market experts. Also, it describes the study of this industry’s financial performance, investments, growth, innovation marks, and new product launches by the top companies and offers deep insights into the current market structure, competitive analysis based on key players, key driving forces, and restraints that affect the demand for growth, opportunities, and risks.

Furthermore, the post-COVID-19 pandemic’s effects on international market restrictions and a deep understanding of how the industry will recover, and strategies are also stated in the report. The competitive landscape has also been examined in detail to provide clarification of the competitive landscape.

This report also discloses the research based on methodologies that define price trend analysis of target companies, collection of data, statistics, target competitors, import-export, information, and previous years’ records based on market sales. Moreover, all the significant factors which influence the market such as small or medium business industry, macro-economic indicators, value chain analysis, and demand-side dynamics, with all the major business players have been explained in detail. This analysis is subject to modification if the key players and feasible analysis of market dynamics change.